NutraLife BioSciences (NLBS) 10-Q 12 Apr 21 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 12, 2021
Cover [Abstract]
Entity Registrant Name	NUTRALIFE BIOSCIENCES, INC
Entity Central Index Key	0001563463
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		160,740,200
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 24,508	$ 14,828
Accounts receivable, net of allowance for doubtful accounts in the amount of $5,919 and $1,500	40,711	11,799
Inventories	522,421	490,173
Prepaid and other current assets	56,492	87,627
Total current assets	644,132	604,427
Property and equipment, net	2,360,854	2,376,647
Operating lease right-of-use assets	880,950	794,531
Intangible assets	638,844	655,086
Other assets	35,000	35,000
Total Assets	4,559,780	4,465,691
Current Liabilities:
Accounts payable	196,216	172,987
Accrued expenses	478,590	413,194
Customer deposits		9,350
Liability for stock to be issued	265,500	265,500
Current portion of finance leases	19,000	20,000
Current portion of operating lease liability	212,100	141,674
Convertible notes, related parties, net of unamortized discount of $195,934 and $290,961	1,604,066	1,164,039
Total current liabilities	2,775,472	2,186,744
Liabilities:
Operating lease liability, net of current portion	669,050	653,057
Finance leases, net of current portion	32,950	36,773
Total liabilities	3,477,472	2,876,574
Stockholders' Equity
Preferred stock; $0.0001 par value, authorized 10,000 shares; no shares issued and outstanding	1	1
Common stock; $0.0001 par value, 499,990,000 authorized shares; 146,234,873 and 140,976,183 shares issued and outstanding	14,618	14,092
Additional paid-in-capital	40,928,382	40,415,885
Accumulated deficit	(39,860,693)	(38,840,861)
Total stockholders' equity	1,082,308	1,589,117
Total Liabilities and Stockholders' Equity	$ 4,559,780	$ 4,465,691

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 5,919	$ 1,500
Unamortized discount	$ 195,934	$ 290,961
Preferred stock, shares par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	499,990,000	499,990,000
Common stock, shares issued	146,234,873	140,976,183
Common stock, shares outstanding	146,234,873	140,976,183

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Net revenue	$ 192,048	$ 720,799
Cost of goods sold	267,463	631,565
Gross profit (loss)	(75,415)	89,234
Operating expenses
Stock-based compensation	47,023	160,581
General and administrative	351,880	901,167
Depreciation and amortization	32,034	21,792
Total operating expenses	430,937	1,083,540
Loss from operations	(506,352)	(994,306)
Other income (expenses)
Other Income (expense)	2,014	(4,385)
Finance costs (including related parties of $512,355)	(515,494)	(289,901)
Total other expense	(513,480)	(294,286)
Net loss before income taxes	(1,019,832)	(1,288,592)
Income tax expense
Net loss	$ (1,019,832)	$ (1,288,592)
Loss per weighted average common share - basic and diluted	$ (0.01)	$ (0.01)
Number of weighted average shares outstanding - basic and diluted	144,189,183	108,264,479

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2020USD ($)
Income Statement [Abstract]
Finance cost related parties	$ 512,355

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 1	$ 9,732	$ 35,638,979	$ (34,833,458)	$ 815,253
Balance, shares at Dec. 31, 2018	1,000	97,315,941
Shares issued for cash		$ 2,806	2,221,674		2,224,480
Shares issued for cash, shares		28,055,061
Shares issued in connection with debt financing		$ 10	18,590		18,600
Shares issued in connection with debt financing, shares		100,000
Shares issued for services		$ 95	160,486		160,581
Shares issued for services, shares		946,281
Shares issued in connection with the purchase of intangible assets		$ 180	318,960		319,140
Shares issued in connection with the purchase of intangible assets, shares		1,800,000
Debt settled through the issuance of stock			380,000		380,000
Net loss				(1,288,592)	(1,288,592)
Balance at Mar. 31, 2019	$ 1	$ 12,823	38,738,689	(36,122,050)	2,629,462
Balance, shares at Mar. 31, 2019	1,000	128,217,283
Balance at Dec. 31, 2019	$ 1	$ 14,092	40,415,885	(38,840,861)	1,589,117
Balance, shares at Dec. 31, 2019	1,000	140,976,183
Shares issued for cash		$ 154	99,846		100,000
Shares issued for cash, shares		1,538,461
Shares issued in connection with debt financing		$ 325	313,775		314,100
Shares issued in connection with debt financing, shares		3,250,000
Shares issued for services		$ 47	46,976		47,023
Shares issued for services, shares		470,229
Beneficial conversion feature			51,900		51,900
Net loss				(1,019,832)	(1,019,832)
Balance at Mar. 31, 2020	$ 1	$ 14,618	$ 40,928,382	$ (39,860,693)	$ 1,082,308
Balance, shares at Mar. 31, 2020	1,000	146,234,873

Consolidated Condensed Statemen

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
OPERATING ACTIVITIES
Net loss	$ (1,019,832)	$ (1,288,592)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	15,793	16,392
Stock-based compensation	47,023	160,581
Stock issued in connection with finance costs		18,600
Amortization of debt discount	461,027	280,400
Amortization of right of use asset	47,945
Amortization of intangible asset	16,242	5,400
Bad debts	4,419
Changes in operating assets and liabilities:
(Increase) in accounts receivable	(33,331)	(71,979)
(Increase) in inventories	(32,248)	(81,588)
Decrease (increase) in prepaid expenses	31,135	(16,594)
(Decrease) increase in accounts payable	23,229	(88,480)
(Decrease) increase in accrued expenses	65,396	(142,104)
(Decrease) in customer deposits	(9,350)	(162)
(Decrease) in operating lease liabilities	(47,945)
Net Cash Used in Operating Activities	(430,497)	(1,208,126)
INVESTING ACTIVITIES
Acquisition of intellectual property		(130,000)
Purchases of property and equipment		(729,507)
Net Cash Used in Investing Activities		(859,507)
FINANCING ACTIVITIES
Proceeds from debt issuances	345,000	200,000
Common shares issued for cash	100,000	2,224,480
Payments on finance leases	(4,823)	(100,000)
Net Cash Provided by Financing Activities	440,177	2,324,480
NET CHANGE IN CASH AND CASH EQUIVALENTS	9,680	256,847
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	14,828	419,975
CASH AND CASH EQUIVALENTS AT END OF PERIOD	24,508	676,822
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest
Shares issued and issuable for the acquisition of intellectual property		584,640
Debt converted to equity		380,000
Shares issued for the issuance of debt	314,100
Beneficial conversion feature	51,900
Right of use asset additions under ASC 842	134,364	781,030
Operating lease liabilities under ASC 842	$ 134,364	$ 795,645

Nature of Operations and Consol

Nature of Operations and Consolidation	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Consolidation	NOTE 1 - NATURE OF OPERATIONS AND CONSOLIDATION NutraLife BioSciences, Inc. F/K/A NutraFuels, Inc. (“We” or the “Company”) is the producer and distributor of nutritional supplements that uses micro molecular formulae and a utilization of an oral spray to provide faster and more efficient absorption. Our products are sold to private label distributers who sell the products we manufacture under their own brand name as well as under our own brand name.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”). In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (which are of a normal recurring nature) necessary for a fair presentation. Interim results are not necessarily indicative of results for a full year. Therefore, the interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, from which the accompanying condensed consolidated balance sheet dated December 31, 2019 was derived. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc., and TransDermalRX, Inc. We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation. Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15th, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies and clarifies certain calculation and presentation matters related to convertible and equity and debt instruments. Specifically, ASU-2020-06 removes requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion features on such instruments. Accounting Standards Update 2020-06 also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the calculation of Diluted EPS. The guidance under ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard using a modified retrospective approach effective January 1, 2021. The Company is currently evaluation the effects of adoption on its consolidated financial statements. Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements. Reclassifications Reclassifications occurred to certain prior period amounts in order to conform to the current presentation. The reclassifications have no effect on the reported net loss. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Cash and Equivalents The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company did not have cash balances in excess of FDIC insured limits at March 31, 2020 and December 31, 2019. Inventories Inventories are stated at lower of cost or net realizable value utilizing the weighted average method of valuation and consist of raw materials and finished goods. The Company reduces inventory on hand to its net realizable value on an item-by-item basis when it is apparent that the expected realizable value of an inventory item falls below its original cost. A charge to cost of sales results when the estimated net realizable value of specific inventory items declines below cost. Management regularly reviews the Company’s inventories for such declines in value. Inventory consists of the following: March 31, 2020 December 31 2019 Raw Materials $ 304,224 $ 206,238 Finished Goods 218,197 283,935 $ 522,421 $ 490,173 Allowance for Doubtful Accounts We establish the existence of bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of our customers. The allowance for doubtful accounts is $5,900 and $1,500 for periods ended March 31, 2020 and December 31, 2019, respectively. Property and Equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, generally three, seven and twelve years, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Leasehold improvements are amortized over their estimated useful lives or the remaining term of the lease, whichever is shorter. Financed assets of $110,372 are included in property and equipment, net as of March 31, 2020 and December 31, 2019. Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value. Impairment charges would be included with costs and expenses in the Company’s condensed consolidated statements of operations and would result in reduced carrying amounts of the related assets on the Company’s condensed consolidated balance sheets. No adjustments were made to long-lived assets during the three month periods ended March 31, 2020. Revenue Recognition The Company accounts for revenue under the guidance of FASB ASC 606, “Revenue from Contracts from Customers” (“ASC 606”). ASC 606 prescribes a five-step model that focuses on transfer of control and entitlement to payment when determining the amount of revenue to be recognized. Under the new guidance, an entity is required to perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company generates revenues from the sale of products. The product is invoiced, and the revenue is recognized upon shipment or once transfer of risk has passed to the customer, which is the point at which the Company has satisfied its performance obligation. Payments received in advance from customers are recorded as customer deposits until earned, at which time revenue is recognized. We recognize certain revenues under bill and hold arrangements with certain customers when the Company has fulfilled all of its performance obligations, the units are segregated for the specific customer only, and the goods are ready for physical transfer to the customer in accordance with their defined contract delivery schedule. For any requested bill and hold arrangement, we make an evaluation as to whether the bill and hold arrangement qualifies for revenue recognition. The customer must initiate the request for the bill and hold arrangement. The customer must make a fixed commitment to purchase he items. The risk of ownership is passed to the customer, and payment terms are not modified. The Company’s revenues accounted for under ASC 606 do not require significant estimates or judgements based on the nature of the Company’s revenue. The Company’s contracts do not include multiple performance obligations or variable consideration. All of the Company’s sales resulted from contracts with customers for the three months ended March 31, 2020 and 2019. Income Taxes The company recorded no income tax expense for the three months ended March 31, 2020 and 2019 because the estimated annual effective tax rate was zero. As of March 31, 2020, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more than likely than not that its deferred tax assets will not be realized. Net Loss Per Share Basic loss per share excludes dilution and is computed by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. The following warrants and convertible notes were three months ended on the net loss per share. March 31, 2020 March 31, 2019 (Shares) (Shares) Warrants 21,819,858 20,994,117 Convertible notes payable, and accrued interest 7,521,897 - 29,341,755 20,994,117 Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount. Leases On January 1, 2019, the Company adopted FASB ASU 2016-02, “Leases” (ASC 842) and other associated standards, which defines a lease as any contract that conveys the right to use a specific asset for a period of time in exchange for consideration. ASC 842 requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet and the disclosure of key information about certain leasing arrangements. As permitted by ASC 842, the Company elected the adoption date of January 1, 2019, which is the initial date of application. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, continues to be reported under ASC Topic 840, “Leases”, or ASC 840, which did not require the recognition of operating lease liabilities on the balance sheet, and is not comparative. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating leases or finance leases (formerly called capital leases). The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in operating expenses. Finance lease charges are split, where amortization of the right-of-use asset is recorded in operating expenses and an implied interest component is recorded in interest expense. The expense recognition for operating leases and finance leases under ASC 842 is substantially consistent with ASC 840. As a result, there is no significant difference in the Company’s results of operations presented in the consolidated statement of operations for each period presented. Leases are classified as a finance lease if any of the following criteria are met: 1. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. 2. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. 3. The lease term is for the major part of the remaining economic life of the underlying asset. 4. The present value of the sum of lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset. 5. The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. For any leases that do not meet the criteria identified above for finance leases, the Company treats such leases as operating leases. As of March 31, 2020, the Company has two finance leases and four operating leases. Under the new guidance, both finance and operating leases are reflected on the balance sheet as lease or “right-of -use” assets and lease liabilities. There are some exceptions, which the Company has elected in its accounting policies. For leases with terms of twelve months or less, or below the Company’s general capitalization policy threshold, the Company elects an accounting policy to not recognize lease assets and lease liabilities for all asset classes. The Company recognizes lease expense for such leases generally on a straight-line basis over the lease term. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and accounts for these options when they are reasonably certain to be exercised. Certain leases contain non-lease components, such as common area maintenance, which are generally accounted for separately. In general, the Company will assess if non-lease components are fixed and determinable, or variable, when determining if the component should be included in the lease liability. For purposes of calculating the present value of the lease obligations, the Company utilizes the implicit interest rate within the lease agreement when known and/or determinable, and otherwise utilizes its incremental borrowing rate at the time of the lease agreement. The related right-of-use asset is initially measured at cost, which primarily comprises of the initial amount of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. Intangible Asset Intangible asset represents the value assigned to intellectual property and is amortized based on the economic benefit expected to be realized.

Liquidity and Going Concern Con

Liquidity and Going Concern Considerations	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern Considerations	NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. We sustained a net loss of approximately $1,020,000 for the three months ended March 31, 2020, and have an accumulated deficit of approximately $39,900,000 at March 31, 2020. These conditions raise substantial doubt about our ability to continue as a going concern. In December 2019, a novel strain of coronavirus was reported to have surfaced in China. The spread of this virus caused various business disruptions including temporary closures to the Company’s offices and facilities. While these disruptions are currently expected to be temporary, there is considerable uncertainty around the duration. Therefore, the Company expects this matter to negatively impact its operating results. The related financial impact and duration cannot be reasonably estimated at this time. The Company is currently in the process of raising capital to complete and finalize the build-out of its facility in Deerfield Beach for the purpose of consolidating its operations. The structure of the capital raise is currently in development. The Company is continuing its path to profitability through increased business development, marketing and sales of the Company’s multiple lines of topical, ingestible and skincare health and wellness products. The Company is also focused on completing an efficacy clinical study on its patented mosquito bug patch with plans upon a successful conclusion to launch globally in the very near future, adding to the Company’s suite of wellness products. Failure to successfully continue to grow operational revenues could harm our profitability and adversely affect our financial condition and results of operations. We face all of the risks inherent in a new business, including the need for significant additional capital, management’s potential underestimation of initial and ongoing costs, and potential delays and other problems in connection with establishing sales channels. We are continuing our plan to further grow and expand operations and seek sources of capital to pay our contractual obligations as they come due. Management believes that its current operating strategy will provide the opportunity for us to continue as a going concern as long as we are able to obtain additional financing; however, there is no assurance this will occur. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	NOTE 4 – PROPERTY AND EQUIPMENT, NET A summary of property and equipment at March 31, 2020 and December 31,2019 is as follows: March 31, 2020 December 31, 2019 (Unaudited) Furniture and equipment $ 1,959,694 $ 1,959,694 Leasehold improvements 840,728 840,728 Property and equipment, at cost 2,800,422 2,800,422 Less: accumulated depreciation (439,568 ) (423,775 ) $ 2,360,854 $ 2,376,647 Depreciation expense for the three months ended March 31, 2020 and 2019 totaled $15,793 and $16,392, respectively.

Intangible Asset

Intangible Asset	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Asset	NOTE 5 – INTANGIBLE ASSET In February 2019, the Company acquired certain intellectual property consisting of patent rights. The aggregate purchase price paid in connection with the patent purchase was $714,640, consisting of $130,000 cash, and 3,300,000 shares of the Company’s common stock valued at $0.177 per share or an aggregate of $584,640. Of the 3,300,000 shares, 1,800,000 shares were provided at closing and 1,500,000 were to be provided one year thereafter. These shares have not been issued and the Company is in negotiations with the seller to extend the issuance of the shares. The acquired patent is amortized over its remaining estimated useful life of approximately 11 years. Amortization for the three months ended March 31, 2020 and 2019 totaled approximately $16,200 and $5,400. The estimated annual amortization expense for the next five years and thereafter is as follows: 2020 (remainder of year) $ 48,758 2021 65,000 2022 65,000 2023 65,000 2024 65,000 Thereafter 330,086 $ 638,844

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Accrued Expenses	NOTE 6 – ACCRUED EXPENSES A summary of accrued expenses is as follows: March 31, 2020 December 31, 2019 (Unaudited) Officer – Bonus $ 325,000 $ 300,000 Accrued Expenses - Other 4,828 9,561 Accrued Interest 80,891 42,059 Other Current Liabilities 67,871 61,574 $ 478,590 $ 413,194

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Notes Payable	NOTE 7 – NOTES PAYABLE During the quarter ended March 31, 2020, the Company received proceeds aggregating $345,000 in connection with multiple short-term promissory notes with due dates ranging from February to June 2020. The notes bear interest at 0% to 12% for the terms of the notes. Each noteholder has the right to convert all the outstanding principal and accrued unpaid interest to the Company’s common stock at a price ranging from $.085 to $.10 per share. Additionally, an aggregate of 3,250,000 shares were issued to the noteholders as additional consideration. The common stock issued to the noteholders are treated as debt discounts. The gross proceeds of the notes were allocated to debt and common shares issued on a relative far value basis. The notes also included a beneficial conversion feature (BCF). The debt discounts associated with the BCF and common stock issuances are amortized through the earlier of the conversion of the notes into common stock, or the maturity date of the notes, on a straight-line basis which approximates the effective interest method due to the short-term nature of the notes. Amortization of the debt discount is reported as finance costs in the Statement of Operations. The Company allocated $314,100 of the gross proceeds of the convertible notes to the stock issuances on a relative fair value basis, which has been recorded as a debt discount. Total amortization associated with stock issuances debt discount was $345,737 for the three months ended March 31, 2020. Because the effective conversion prices of these notes were less than the fair value of the underlying common stock on the issuance date, the Company allocated $51,900, the intrinsic value of that beneficial conversion feature, to additional paid-in capital. Total amortization associated with the beneficial conversion feature debt discount was $91,281 for the three months ended March 31, 2020.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	NOTE 8 - STOCKHOLDERS’ EQUITY During the quarter ended March 31, 2020, the Company issued 1,538,461 shares of common stock for $.065 per share, for an aggregate of $100,000. During the quarter ended March 31, 2020, the Company issued 470,229 shares of common stock for services aggregating $47,023, valued using the trading price on the date of issuance. The Company recorded $51,900 to additional paid-in capital resulting from the beneficial conversion feature. Series A Preferred Stock The Company has 10,000 shares of Preferred Stock authorized. 1,000 shares have been designated as Series A Preferred Stock and is not entitled to dividends or liquidation preferences. Each share has voting rights equal to 500,000 shares of the Company’s common stock. In 2012, Edgar Ward, the Company’s President, CEO, and director, was granted 1,000 shares of Series A voting stock for $1,000. Series B Preferred Stock In September, 2020, the Company authorized 110 shares of Series B Convertible Preferred Stock. A Series B Holder will have the right from time to time, and at any time following January 1, 2021, to convert each outstanding share of Series B stock into shares of common stock at a rate of 149,567 shares of common stock for each share of Series B Preferred Stock. Each share of Series B Preferred Stock shall have a number of votes equal to the number of conversion shares which would be issuable as of the date of such vote. The Series B Preferred Stock does not have any liquidation preference. Subsequent issuances : In April through December 2020, the Company issued an additional 384,615 shares for $.065 per share. In November 2020, the Company issued 12,500,000 shares of common stock in exchange for 250 shares of Series X Convertible Preferred Stock of Lord Global Corporation in connection with a Stock Purchase Agreement. In September 2020, the Company issued 20 shares of Series B Convertible Preferred Stock to three consultants as part of their compensation arrangements.

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	NOTE 9 – LEASES In conjunction with the new guidance for leases, as defined by the FASB with ASU 2016-02, Leases The Company leases their office and warehouse facilities located in in Coconut Creek, Florida under a non-cancelable operating lease agreement that expires in February 2022. In June 2017, the Company entered into a lease for an additional facility located in Deerfield Beach, Florida under a non-cancelable operating lease. The term of the lease is for 86 months beginning on January 1, 2018 and calls for yearly 3% increases to base rent, with monthly payments that commenced in March 2018. In July and September of 2019, the Company’s wholly owned subsidiary, Phytochem, entered into two separate lease agreements for office and warehouse space located in Onalaska, Wisconsin, that commenced on August 1 and October 1, respectively. Each lease is for six-month terms with four (4) renewal options to extend for six additional months. The Company expects to occupy these facilities for the full term of these leases totaling 30 months and the leases call for annual 3% increases to base rent. In the March 31, 2020 condensed consolidated balance sheet, the Company has recorded right-of-use assets of approximately $881,000 and a lease liability of $881,000, of which $212,000 is reported as a current liability. The weighted average remaining lease term is 51 months and weighted average discount rate used is 10%. The following table presents a reconciliation of the undiscounted future minimum lease payments remaining under the operating lease reported as operating lease liability on the condensed consolidated balance sheet as of March 31, 2020: Undiscounted future minimum lease payments: 2020 (remainder of year) $ 231,883 2021 283,200 2022 199,000 2023 189,400 2024 195,100 Total undiscounted future minimum lease payments 1,098,583 Less: amount representing imputed interest (217,433 ) Operating lease liability $ 881,150 Supplemental cash flow information related to leases is as follows, for the three months ended March 31, March 31, 2020 March 31 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 63,139 $ 221,331 Lease expense for the operating leases was approximately $63,140 and $80,315 for the quarters ended March 31, 2020 and 2019, respectively. Finance Leases: The Company has acquired certain equipment under agreements that are classified as finance leases. The cost of the equipment under finance leases is included in the balance sheet as property and equipment. The finance lease equipment was approximately $110,000 as of March 31, 2020 and December 31, 2019, and is not yet in service, accordingly there has been no depreciation expense on this equipment. Minimum lease payments required by these finance leases are as follows: Undiscounted future minimum lease payments: 2020 (remainder of year) $ 17,900 2021 24,000 2022 17,000 2023 2,100 Total undiscounted future minimum lease payments 61,000 Less: amount representing interest (9,100 ) Less: current portion (19,000 ) Present value of minimum lease payments, net of current portion $ 32,900

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 10-COMMITMENTS AND CONTINGENCIES The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company’s financial position or results of operations. As of March 31, 2020, the Company is not aware of any asserted claims.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 11-SUBSEQUENT EVENTS In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in China, and began to spread around the world in early 2020. In reaction to decreased supply of and increased demand for sanitizer products, the Company shifted its manufacturing to produce sanitizer products. The Company’s other business operations have been impacted negatively by COVID-19 to continue to negatively impact its operating results and its ability to obtain financing. From April through December 2020, the Company issued warrants totaling 5,540,740 in exchange for cash proceeds of $125,000. The exercise prices range from $0.08 - $0.10 and expire 2 – 3 years after issuance. In January 2021, the Company issued 15,000,000 warrants to its Chief Executive Officer, President and sole Director as compensation. The warrants price of $0.1025 and expire 3 years after issuance. During January and February 2021, the Company issued warrants totaling 5,600,000 as additional consideration for proceeds from notes. The warrants have an exercise price of $0.08 and expire 3 years after issuance. Litigation: In 2020, a claim has been filed against the Company by its former attorney. The claim involves allegations that fees approximating $150,000 charged for the calendar year 2019 were unpaid. The Company is vigorously contesting these claims and the outcome cannot be determined at this time. In 2020, a claim was filed against the Company for a breach of confidentiality imposed by a non-disclosure agreement signed by both the Company and plaintiff. The claim was dismissed in February 2021.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America (“U.S.”) as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”). In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (which are of a normal recurring nature) necessary for a fair presentation. Interim results are not necessarily indicative of results for a full year. Therefore, the interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, from which the accompanying condensed consolidated balance sheet dated December 31, 2019 was derived.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc., and TransDermalRX, Inc. We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15th, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies and clarifies certain calculation and presentation matters related to convertible and equity and debt instruments. Specifically, ASU-2020-06 removes requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion features on such instruments. Accounting Standards Update 2020-06 also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the calculation of Diluted EPS. The guidance under ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard using a modified retrospective approach effective January 1, 2021. The Company is currently evaluation the effects of adoption on its consolidated financial statements. Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.
Reclassifications	Reclassifications Reclassifications occurred to certain prior period amounts in order to conform to the current presentation. The reclassifications have no effect on the reported net loss.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Cash and Equivalents	Cash and Equivalents The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company did not have cash balances in excess of FDIC insured limits at March 31, 2020 and December 31, 2019.
Inventories	Inventories Inventories are stated at lower of cost or net realizable value utilizing the weighted average method of valuation and consist of raw materials and finished goods. The Company reduces inventory on hand to its net realizable value on an item-by-item basis when it is apparent that the expected realizable value of an inventory item falls below its original cost. A charge to cost of sales results when the estimated net realizable value of specific inventory items declines below cost. Management regularly reviews the Company’s inventories for such declines in value. Inventory consists of the following: March 31, 2020 December 31 2019 Raw Materials $ 304,224 $ 206,238 Finished Goods 218,197 283,935 $ 522,421 $ 490,173
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts We establish the existence of bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of our customers. The allowance for doubtful accounts is $5,900 and $1,500 for periods ended March 31, 2020 and December 31, 2019, respectively.
Property and Equipment	Property and Equipment All property and equipment are recorded at cost and depreciated over their estimated useful lives, generally three, seven and twelve years, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Leasehold improvements are amortized over their estimated useful lives or the remaining term of the lease, whichever is shorter. Financed assets of $110,372 are included in property and equipment, net as of March 31, 2020 and December 31, 2019.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value. Impairment charges would be included with costs and expenses in the Company’s condensed consolidated statements of operations and would result in reduced carrying amounts of the related assets on the Company’s condensed consolidated balance sheets. No adjustments were made to long-lived assets during the three month periods ended March 31, 2020.
Revenue Recognition	Revenue Recognition The Company accounts for revenue under the guidance of FASB ASC 606, “Revenue from Contracts from Customers” (“ASC 606”). ASC 606 prescribes a five-step model that focuses on transfer of control and entitlement to payment when determining the amount of revenue to be recognized. Under the new guidance, an entity is required to perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company generates revenues from the sale of products. The product is invoiced, and the revenue is recognized upon shipment or once transfer of risk has passed to the customer, which is the point at which the Company has satisfied its performance obligation. Payments received in advance from customers are recorded as customer deposits until earned, at which time revenue is recognized. We recognize certain revenues under bill and hold arrangements with certain customers when the Company has fulfilled all of its performance obligations, the units are segregated for the specific customer only, and the goods are ready for physical transfer to the customer in accordance with their defined contract delivery schedule. For any requested bill and hold arrangement, we make an evaluation as to whether the bill and hold arrangement qualifies for revenue recognition. The customer must initiate the request for the bill and hold arrangement. The customer must make a fixed commitment to purchase he items. The risk of ownership is passed to the customer, and payment terms are not modified. The Company’s revenues accounted for under ASC 606 do not require significant estimates or judgements based on the nature of the Company’s revenue. The Company’s contracts do not include multiple performance obligations or variable consideration. All of the Company’s sales resulted from contracts with customers for the three months ended March 31, 2020 and 2019.
Income Taxes	Income Taxes The company recorded no income tax expense for the three months ended March 31, 2020 and 2019 because the estimated annual effective tax rate was zero. As of March 31, 2020, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more than likely than not that its deferred tax assets will not be realized.
Net Loss Per Share	Net Loss Per Share Basic loss per share excludes dilution and is computed by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the period and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. The following warrants and convertible notes were three months ended on the net loss per share. March 31, 2020 March 31, 2019 (Shares) (Shares) Warrants 21,819,858 20,994,117 Convertible notes payable, and accrued interest 7,521,897 - 29,341,755 20,994,117
Related Party Transactions	Related Party Transactions All transactions with related parties are in the normal course of operations and are measured at the exchange amount.
Leases	Leases On January 1, 2019, the Company adopted FASB ASU 2016-02, “Leases” (ASC 842) and other associated standards, which defines a lease as any contract that conveys the right to use a specific asset for a period of time in exchange for consideration. ASC 842 requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet and the disclosure of key information about certain leasing arrangements. As permitted by ASC 842, the Company elected the adoption date of January 1, 2019, which is the initial date of application. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated, continues to be reported under ASC Topic 840, “Leases”, or ASC 840, which did not require the recognition of operating lease liabilities on the balance sheet, and is not comparative. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating leases or finance leases (formerly called capital leases). The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in operating expenses. Finance lease charges are split, where amortization of the right-of-use asset is recorded in operating expenses and an implied interest component is recorded in interest expense. The expense recognition for operating leases and finance leases under ASC 842 is substantially consistent with ASC 840. As a result, there is no significant difference in the Company’s results of operations presented in the consolidated statement of operations for each period presented. Leases are classified as a finance lease if any of the following criteria are met: 1. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. 2. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. 3. The lease term is for the major part of the remaining economic life of the underlying asset. 4. The present value of the sum of lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset. 5. The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. For any leases that do not meet the criteria identified above for finance leases, the Company treats such leases as operating leases. As of March 31, 2020, the Company has two finance leases and four operating leases. Under the new guidance, both finance and operating leases are reflected on the balance sheet as lease or “right-of -use” assets and lease liabilities. There are some exceptions, which the Company has elected in its accounting policies. For leases with terms of twelve months or less, or below the Company’s general capitalization policy threshold, the Company elects an accounting policy to not recognize lease assets and lease liabilities for all asset classes. The Company recognizes lease expense for such leases generally on a straight-line basis over the lease term. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and accounts for these options when they are reasonably certain to be exercised. Certain leases contain non-lease components, such as common area maintenance, which are generally accounted for separately. In general, the Company will assess if non-lease components are fixed and determinable, or variable, when determining if the component should be included in the lease liability. For purposes of calculating the present value of the lease obligations, the Company utilizes the implicit interest rate within the lease agreement when known and/or determinable, and otherwise utilizes its incremental borrowing rate at the time of the lease agreement. The related right-of-use asset is initially measured at cost, which primarily comprises of the initial amount of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense.
Intangible Asset	Intangible Asset Intangible asset represents the value assigned to intellectual property and is amortized based on the economic benefit expected to be realized.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Schedule of Inventories	Inventory consists of the following: March 31, 2020 December 31 2019 Raw Materials $ 304,224 $ 206,238 Finished Goods 218,197 283,935 $ 522,421 $ 490,173
Schedule of Warrants and Convertible Notes Excluded from Computation of Net Loss Per Share	The following warrants and convertible notes were three months ended on the net loss per share. March 31, 2020 March 31, 2019 (Shares) (Shares) Warrants 21,819,858 20,994,117 Convertible notes payable, and accrued interest 7,521,897 - 29,341,755 20,994,117

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	A summary of property and equipment at March 31, 2020 and December 31,2019 is as follows: March 31, 2020 December 31, 2019 (Unaudited) Furniture and equipment $ 1,959,694 $ 1,959,694 Leasehold improvements 840,728 840,728 Property and equipment, at cost 2,800,422 2,800,422 Less: accumulated depreciation (439,568 ) (423,775 ) $ 2,360,854 $ 2,376,647

Intangible Asset (Tables)

Intangible Asset (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Estimate Amortization Expense	The estimated annual amortization expense for the next five years and thereafter is as follows: 2020 (remainder of year) $ 48,758 2021 65,000 2022 65,000 2023 65,000 2024 65,000 Thereafter 330,086 $ 638,844

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Payables and Accruals [Abstract]
Summary of Accrued Expenses	A summary of accrued expenses is as follows: March 31, 2020 December 31, 2019 (Unaudited) Officer – Bonus $ 325,000 $ 300,000 Accrued Expenses - Other 4,828 9,561 Accrued Interest 80,891 42,059 Other Current Liabilities 67,871 61,574 $ 478,590 $ 413,194

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule of Operating Leases Undiscounted Future Minimum Lease Payments	Undiscounted future minimum lease payments: 2020 (remainder of year) $ 231,883 2021 283,200 2022 199,000 2023 189,400 2024 195,100 Total undiscounted future minimum lease payments 1,098,583 Less: amount representing imputed interest (217,433 ) Operating lease liability $ 881,150
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases is as follows, for the three months ended March 31, March 31, 2020 March 31 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 63,139 $ 221,331
Schedule of Finance Leases Undiscounted Future Minimum Lease Payments	Undiscounted future minimum lease payments: 2020 (remainder of year) $ 17,900 2021 24,000 2022 17,000 2023 2,100 Total undiscounted future minimum lease payments 61,000 Less: amount representing interest (9,100 ) Less: current portion (19,000 ) Present value of minimum lease payments, net of current portion $ 32,900

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 5,919		$ 1,500
Financed assets	110,372		$ 110,372
Income tax expense

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Raw Materials	$ 304,224	$ 206,238
Finished Goods	218,197	283,935
Inventories	$ 522,421	$ 490,173

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Warrants and Convertible Notes Excluded from Computation of Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities	29,341,755	20,994,117
Warrant [Member]
Antidilutive Securities	21,819,858	20,994,117
Convertible Notes Payable and Accrued Interest [Member]
Antidilutive Securities	7,521,897

Liquidity and Going Concern C_2

Liquidity and Going Concern Considerations (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (1,019,832)	$ (1,288,592)
Accumulated deficit	$ (39,860,693)		$ (38,840,861)

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 15,793	$ 16,392

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Property and equipment, at cost	$ 2,800,422	$ 2,800,422
Less: accumulated depreciation	(439,568)	(423,775)
Property and equipment, net	2,360,854	2,376,647
Furniture and Equipment [Member]
Property and equipment, at cost	1,959,694	1,959,694
Leasehold Improvements [Member]
Property and equipment, at cost	$ 840,728	$ 840,728

Intangible Asset (Details Narra

Intangible Asset (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 28, 2019	Mar. 31, 2020	Mar. 31, 2019
Payments to acquire intangible assets			$ 130,000
Amortization		$ 16,242	$ 5,400
Common Stock [Member]
Shares issued, price per share		$ .065
Patents [Member]
Consideration to acquire intangible assets	$ 714,640
Payments to acquire intangible assets	$ 130,000
Remaining estimated useful life	11 years
Patents [Member] | Common Stock [Member]
Stock issued during period, shares, purchase of assets	3,300,000
Shares issued, price per share	$ 0.177
Stock issued during period, value, purchase of assets	$ 584,640
Issuance of shares description	Of the 3,300,000 shares, 1,800,000 shares were provided at closing and 1,500,000 were to be provided one year thereafter.

Intangible Asset - Schedule of

Intangible Asset - Schedule of Estimate Amortization Expense (Details)	Mar. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2020 (remainder of year)	$ 48,758
2021	65,000
2022	65,000
2023	65,000
2024	65,000
Thereafter	330,086
Estimated Amortization Expense	$ 638,844

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Officer - Bonus	$ 325,000	$ 300,000
Accrued Expenses - Other	4,828	9,561
Accrued Interest	80,891	42,059
Other Current Liabilities	67,871	61,574
Accrued Liabilities	$ 478,590	$ 413,194

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Debt instrument, beneficial conversion feature	$ 51,900
Amortization of debt discount	$ 461,027	$ 280,400
Noteholders [Member]
Shares were issued	3,250,000
Short Term Promissory Note Payable [Member]
Proceeds from notes payable	$ 345,000
Debt instrument, maturity date, description	Due dates ranging from February to June 2020.
Short Term Promissory Note Payable [Member] | Minimum [Member]
Debt instrument interest rate	0.00%
Debt conversion price per share	$ 0.085
Short Term Promissory Note Payable [Member] | Maximum [Member]
Debt instrument interest rate	12.00%
Debt conversion price per share	$ 0.10
Convertible Notes Payable [Member]
Proceeds from issuance of stock	$ 314,100
Amortization of debt issuance costs and discounts	$ 345,737

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended	12 Months Ended
	Nov. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2012	Sep. 30, 2020	Dec. 31, 2019
Value of shares issued for services		$ 47,023	$ 160,581
Beneficial conversion feature additional paid in capital		51,900
Value of stock issued during the period		$ 100,000	$ 2,224,480
Preferred stock, shares authorized		10,000					10,000
Subsequent Event [Member]
Stock issued during the period, shares				384,615
Per share price of stock				$ .065
Series A Preferred Stock [Member]
Stock issued during the period, shares					1,000
Value of stock issued during the period					$ 1,000
Preferred stock, shares authorized		1,000
Preferred stock, voting rights		Each share has voting rights equal to 500,000 shares of the Company's common stock.
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized						110
Convertible preferred stock shares issued						149,567
Series X Preferred Stock [Member] | Subsequent Event [Member] | Stock Purchase Agreement [Member] | Lord Global Corporation [Member]
Stock issued during the period, shares	12,500,000
Shares issued in connection with convertible debt	250
Series B Preferred Stock [Member] | Subsequent Event [Member]
Convertible preferred stock shares issued						20
Common Stock [Member]
Stock issued during the period, shares		1,538,461	28,055,061
Per share price of stock		$ .065
Aggregate share value of common stock		$ 100,000
Shares issued for services		470,229	946,281
Value of shares issued for services		$ 47	$ 95
Value of stock issued during the period		$ 154	$ 2,806

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 30, 2017	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Operating lease, right-of-use asset		$ 880,950		$ 794,531
Operating lease liability		881,150
Operating lease, current liability		$ 212,100		141,674
Weighted average remaining lease term		51 months
Weighted average discount rate		10.00%
Operating lease expense		$ 63,140	$ 80,315
Finance lease equipment		$ 110,000		$ 110,000
Phytochem [Member]
Description of operating lease		In July and September of 2019, the Company's wholly owned subsidiary, Phytochem, entered into two separate lease agreements for office and warehouse space located in Onalaska, Wisconsin, that commenced on August 1 and October 1, respectively. Each lease is for six-month terms with four (4) renewal options to extend for six additional months. The Company expects to occupy these facilities for the full term of these leases totaling 30 months and the leases call for annual 3% increases to base rent.
Lessee, operating lease, term of contract		30 months
Annual increases to base rent percent		3.00%
Coconut Creek, Florida [Member]
Operating lease expires, date		2022-02
Deerfield Beach, Florida [Member]
Description of operating lease	The Company entered into a lease for an additional facility located in Deerfield Beach, Florida under a non-cancelable operating lease. The term of the lease is for 86 months beginning on January 1, 2018 and calls for yearly 3% increases to base rent, with monthly payments that commenced in March 2018.
Lessee, operating lease, term of contract	86 months
Annual increases to base rent percent	3.00%

Leases - Schedule of Operating

Leases - Schedule of Operating Leases Undiscounted Future Minimum Lease Payments (Details)	Mar. 31, 2020USD ($)
Leases [Abstract]
2020 (remainder of year)	$ 231,883
2021	283,200
2022	199,000
2023	189,400
2024	195,100
Total undiscounted future minimum lease payments	1,098,583
Less: amount representing imputed interest	(217,433)
Operating lease liability	$ 881,150

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related To Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 63,139	$ 221,331

Leases - Schedule of Finance Le

Leases - Schedule of Finance Leases Undiscounted Future Minimum Lease Payments (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2020 (remainder of year)	$ 17,900
2021	24,000
2022	17,000
2023	2,100
Total undiscounted future minimum lease payments	61,000
Less: amount representing interest	(9,100)
Less: current portion	(19,000)	$ (20,000)
Present value of minimum lease payments, net of current portion	$ 32,950	$ 36,773

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	1 Months Ended	2 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2021	Feb. 28, 2021	Dec. 31, 2020	Dec. 31, 2020
Number of warrants issued		5,600,000	5,540,740
Cash proceeds from warrants			$ 125,000
Warrants exercise price		$ 0.08
Warrants expiry term		3 years
Chief Executive Officer President and Director [Member]
Number of warrants issued	15,000,000
Warrants exercise price	$ 0.1025
Warrants expiry term	3 years
Former Attorney [Member]
Damages sought value				$ 150,000
Minimum [Member]
Warrants exercise price			$ 0.08	$ 0.08
Warrants expiry term			2 years
Maximum [Member]
Warrants exercise price			$ 0.10	$ 0.10
Warrants expiry term			3 years